sábado, 7 de enero de 2017

Developing Regulatory Methods for Characterizing Nanomaterials in FDA-Regulated Products

fda header

FDA Grand Rounds

Science Rounds Picture

The Jan. 12 FDA Grand Rounds webcast presents the latest in FDA nanomaterials research
Register here for CE Credit

Developing Regulatory Methods for Characterizing Nanomaterials in FDA-Regulated Products

Thursday, January 12, 2017
12:00 p.m. -1:00 p.m. EST
Presented by 
Dr. Thilak Mudalige
Research Chemist
FDA's Office of Regulatory Affairs

3 Things You’ll Take Away From This FDA Chemist:

1) An overview of nanomaterials and their size-dependent properties
2) Everyday products you use that contain inorganic nanomaterials
3) Dr. Mudalige’s methodology for characterizing the properties of nanomaterials in FDA-regulated products in an effort to understand their health impacts 

About the Presentation

FDA is seeing an increasing use of nanoparticles in consumer and medical products because of their unique, beneficial properties.  Silver nanoparticles, for example, are used in wound dressing for their antimicrobial properties and titanium dioxide nanoparticles in sunscreen to block ultraviolet radiation.  However, FDA needs to better understand the health effects of nanoparticles.  FDA’s Dr. Thilak Mudalige will describe the methodology he developed for characterizing inorganic and organic nanoparticles.

Did You Miss Our Last Grand Rounds?

No worries! Dr. Richard Beger’s entire presentation on Metabolomics and Proteomics Biomarkers: Discovery and Validation in Toxicity Studies is now available for your viewing pleasure.

And keep up with the latest advancements in regulatory science through FDA's academic partners, the FDA Centers of Excellence in Regulatory Science and Innovation, which feature the CERSI Lecture Series as well as workshops, publications, research, and fellowships

No hay comentarios:

Publicar un comentario